UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: Common Stock
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 29, 2023, Lantern Pharma Inc. (the “Company”) entered into (i) an amendment to the employment agreement between the Company and Kishor G. Bhatia, the Company’s Chief Scientific Officer, and (ii) an amendment to the employment agreement between the Company and David R. Margrave, the Company’s Chief Financial Officer.
Pursuant to the amendment entered into with Dr. Bhatia, the annual pre-tax base salary level for Dr. Bhatia was increased to $316,000 commencing January 1, 2024, and the target eligible annual bonus level percentage under Dr. Bhatia’s employment agreement was increased to 40% of Dr. Bhatia’s applicable base salary.
Pursuant to the amendment entered into with Mr. Margrave, the annual pre-tax base salary level for Mr. Margrave was increased to $413,800 commencing January 1, 2024, and the target eligible annual bonus level percentage under Mr. Margrave’s employment agreement was increased to 40% of Mr. Margrave’s applicable base salary.
The amendments entered into with Dr. Bhatia and Mr. Margrave were recommended by the Company’s Compensation Committee and authorized by the Company’s Board of Directors following an evaluation that included consideration of a compensation evaluation report and analysis prepared by an independent compensation advisory firm.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lantern Pharma Inc., | ||
A Delaware Corporation | ||
Dated: December 29, 2023 | By: | /s/ David R. Margrave |
David R. Margrave, Chief Financial Officer |
3 |
Cover |
Dec. 29, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 29, 2023 |
Entity File Number | 001-39318 |
Entity Registrant Name | Lantern Pharma Inc. |
Entity Central Index Key | 0001763950 |
Entity Tax Identification Number | 46-3973463 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 1920 McKinney Avenue |
Entity Address, Address Line Two | 7th Floor |
Entity Address, City or Town | Dallas |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 75201 |
City Area Code | (972) |
Local Phone Number | 277-1136 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | LTRN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | true |
-8?20$3;8T.P6BP^0"X9
M9K>]9!:G